Prelude Therapeutics designs and develops small molecule therapies targeting key drivers of cancer cell growth and resistance.
Prelude Therapeutics has raised $90.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2026.
Prelude Therapeutics's investors include RA Capital Management, OrbiMed, Fidelity, Soleus Capital, Incyte.
Prelude Therapeutics is headquartered in Wilmington, United States.
Prelude Therapeutics designs and develops small molecule therapies targeting key drivers of cancer cell growth and resistance.
Prelude Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Prelude Therapeutics — Funding & Investors." VCBacked, April 21, 2026, https://www.vcbacked.co/company/prelude-therapeutics. Accessed July 19, 2026.
VCBacked. (2026). Prelude Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/prelude-therapeutics
{{cite web |title=Prelude Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/prelude-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated